

ERRATUM

Open Access

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

Hideaki Katagiri^{1*}, Shinji Fujikoshi¹, Takuya Suzuki², Kiyoshi Fujita³, Naoya Sugiyama⁴, Michihiro Takahashi^{1,6} and Juan-Carlos Gomez⁵

Correction

After the publication of this work [1], we became aware that it contains inaccurate description. The correct description on page 5 was “At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups ($p < .01$) (Figure one)”, and not “At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups ($p < .001$) (Figure one).” We regret any inconvenience that this inaccuracy might have caused.

Author details

¹Lilly Research Laboratories Japan, Eli Lilly Japan KK, Kobe, Japan. ²Ayase Hospital, 6-3-1 Ayase, Adachi-ku, Tokyo 120-0005, Japan. ³Seishinkai Okehazama Hospital Fujita Kokoro Care Center, 3-879 Sakaecho Minamiyakata, Toyoake-shi, Aichi 470-1168, Japan. ⁴Numazu Chuo Hospital, 24-1 Nakasecho, Numazu-shi, Shizuoka 410-0811, Japan. ⁵Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA. ⁶Takahashi Psychiatric Clinic, Ashiya, Hyogo, Japan.

Received: 27 August 2014 Accepted: 27 August 2014

Published online: 10 December 2014

Reference

1. Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. *BMC Psychiatry* 2013, **13**:20.

doi:10.1186/s12888-014-0313-9

Cite this article as: Katagiri et al.: Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. *BMC Psychiatry* 2014 **14**:313.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 BioMed Central

* Correspondence: katagiri_hideaki@lilly.com

¹Lilly Research Laboratories Japan, Eli Lilly Japan KK, Kobe, Japan